DCPH Deciphera Pharmaceuticals Inc

Price (delayed)

$13.73

Market cap

$909.15M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.89

Enterprise value

$843.98M

Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. The Company is leveraging its proprietary switch-control kinase ...

Highlights
Deciphera Pharmaceuticals's revenue has increased by 49% YoY and by 4.2% QoQ
The gross profit is up by 46% year-on-year and by 4.2% since the previous quarter
Deciphera Pharmaceuticals's quick ratio has plunged by 61% YoY but it has increased by 2.2% from the previous quarter
The net income has contracted by 12% YoY but it has grown by 4.8% from the previous quarter
Deciphera Pharmaceuticals's equity has decreased by 46% YoY and by 11% QoQ
Deciphera Pharmaceuticals's gross margin has decreased by 2.4% YoY

Key stats

What are the main financial stats of DCPH
Market
Shares outstanding
66.22M
Market cap
$909.15M
Enterprise value
$843.98M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.96
Price to sales (P/S)
8.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.42
Earnings
Revenue
$100.22M
EBIT
-$285.56M
EBITDA
-$278.93M
Free cash flow
-$225.83M
Per share
EPS
-$4.89
Free cash flow per share
-$3.85
Book value per share
$4.64
Revenue per share
$1.71
TBVPS
$6.58
Balance sheet
Total assets
$385.46M
Total liabilities
$113.9M
Debt
$30.16M
Equity
$271.57M
Working capital
$233.17M
Liquidity
Debt to equity
0.11
Current ratio
3.69
Quick ratio
3.23
Net debt/EBITDA
0.23
Margins
EBITDA margin
-278.3%
Gross margin
96.9%
Net margin
-284.9%
Operating margin
-284.9%
Efficiency
Return on assets
-62.1%
Return on equity
-81.4%
Return on invested capital
-87.3%
Return on capital employed
-95.6%
Return on sales
-284.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DCPH stock price

How has the Deciphera Pharmaceuticals stock price performed over time
Intraday
-1.79%
1 week
16.95%
1 month
27.6%
1 year
-61.81%
YTD
40.53%
QTD
48.11%

Financial performance

How have Deciphera Pharmaceuticals's revenue and profit performed over time
Revenue
$100.22M
Gross profit
$97.12M
Operating income
-$285.48M
Net income
-$285.56M
Gross margin
96.9%
Net margin
-284.9%
Deciphera Pharmaceuticals's revenue has increased by 49% YoY and by 4.2% QoQ
The gross profit is up by 46% year-on-year and by 4.2% since the previous quarter
The company's operating margin rose by 26% YoY and by 9% QoQ
The net margin has increased by 25% year-on-year and by 9% since the previous quarter

Growth

What is Deciphera Pharmaceuticals's growth rate over time

Valuation

What is Deciphera Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.96
P/S
8.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.42
The company's EPS fell by 9% YoY but it rose by 5% QoQ
Deciphera Pharmaceuticals's equity has decreased by 46% YoY and by 11% QoQ
The P/B is 28% below the 5-year quarterly average of 4.1 and 15% below the last 4 quarters average of 3.5
Deciphera Pharmaceuticals's revenue has increased by 49% YoY and by 4.2% QoQ
DCPH's price to sales (P/S) is 45% less than its last 4 quarters average of 14.6

Efficiency

How efficient is Deciphera Pharmaceuticals business performance
The return on equity has dropped by 79% year-on-year and by 11% since the previous quarter
Deciphera Pharmaceuticals's return on invested capital has shrunk by 58% YoY and by 4.4% QoQ
The ROA has plunged by 57% YoY and by 6% from the previous quarter
The company's return on sales rose by 25% YoY and by 9% QoQ

Dividends

What is DCPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DCPH.

Financial health

How did Deciphera Pharmaceuticals financials performed over time
Deciphera Pharmaceuticals's quick ratio has plunged by 61% YoY but it has increased by 2.2% from the previous quarter
Deciphera Pharmaceuticals's current ratio has shrunk by 57% YoY but it has increased by 5% QoQ
The debt is 89% smaller than the equity
DCPH's debt to equity has soared by 83% YoY and by 10% from the previous quarter
Deciphera Pharmaceuticals's equity has decreased by 46% YoY and by 11% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.